2826 Secobarbital Secobarbital is only found in individuals that have used or taken this drug. It is a barbiturate derivative drug. It possesses anaesthetic, anticonvulsant, sedative and hypnotic properties. In the United Kingdom, it was known as Quinalbarbitone. Secobarbital binds at a distinct binding site associated with a Cl^- ionopore at the GABA_A receptor, increasing the duration of time for which the Cl^- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. 76-73-3 5193 C12H18N2O3 238.131740 White powder. 100°C 550 mg/L Oral (L1388); Parenteral (L1388); Rectal (L1388). Secobarbital binds at a distinct binding site associated with a Cl^- ionopore at the GABA_A receptor, increasing the duration of time for which the Cl^- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. Route of Elimination: Barbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine and, less commonly, in the feces. No indication of carcinogenicity to humans (not listed by IARC). For the Short-term treatment of intractable insomnia for patients habituated to barbiturates Secobarbital causes slurred speech, disorientation and "drunken" behavior. It is physically and psychologically addictive. Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death. 2009-07-21T20:26:51Z 2014-12-24T20:25:51Z Secobarbital 9073 Secobarbital DB00418 true CCCC(C)C1(CC=C)C(O)=NC(=O)N=C1O C12H18N2O3 InChI=1/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17) InChIKey=KQPKPCNLIDLUMF-UHFFFAOYNA-N 238.2829 238.131742452 Exogenous Solid 1.97 HMDB14562 CHEMBL447 5005